Ionis Pharmaceuticals IONS Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $372.26M+53.8% | $242.08M-39.4% | $399.27M+44.4% | $276.47M-68.2% | ||
| $1.58B+12.5% | $1.4B-27.4% | $1.93B+13.0% | $1.71B+37.3% | ||
| $10.05M-19.7% | $12.51M+68.1% | $7.44M-66.2% | $22.03M-11.2% | ||
| $2.99B+14.1% | $2.62B-0.8% | $2.64B+19.9% | $2.2B-6.1% | ||
| $123.05M+30.6% | $94.25M+32.7% | $71.04M-4.4% | $74.29M-58.3% | ||
| $2.31B+12.1% | $2.06B— | —— | —— | ||
| $3.52B+17.3% | $3B+0.5% | $2.99B+18.0% | $2.53B-3.0% | ||
| $28.08M-34.6% | $42.96M+65.1% | $26.03M+45.2% | $17.92M+50.5% | ||
| $73.76M-6.6% | $78.99M-47.7% | $151.13M+66.9% | $90.58M-7.3% | ||
| $431.95M— | $0-100% | $44.33M— | $0— | ||
| $781.57M+153% | $309.32M-31.0% | $448.09M+43.8% | $311.56M+29.5% | ||
| $3.03B+25.6% | $2.42B-7.2% | $2.6B+32.8% | $1.96B+6.6% | ||
| 300M0.0% | 300M+208,233% | 144K+1.4% | 142K+0.7% | ||
| -$2.63B-17.0% | -$2.25B-25.3% | -$1.8B-25.6% | -$1.43B-23.3% | ||
| $489.09M-16.9% | $588.35M+52.2% | $386.69M-32.5% | $572.89M-25.8% | ||
| $3.52B+17.3% | $3B+0.5% | $2.99B+18.0% | $2.53B-3.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ionis Pharmaceuticals's total assets?
- Ionis Pharmaceuticals (IONS) holds $3.4B in total assets, up 22.7% year over year.
- How much debt does Ionis Pharmaceuticals have?
- Ionis Pharmaceuticals carries $691.7M in total debt against $491.4M of shareholders' equity, a debt-to-equity ratio of 1.41.
- How much cash does Ionis Pharmaceuticals have?
- Ionis Pharmaceuticals holds $173.4M in cash and equivalents.
- Can Ionis Pharmaceuticals cover its short-term obligations?
- Its current ratio is 4.10 — current assets exceed current liabilities.
- Where does Ionis Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Ionis Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
